Caplin Point Laboratories (524742) Q2 24/25 earnings summary

Executive summary

• Q2 FY25 revenue grew 18% year-over-year, with H1 FY25 revenue reaching ₹942 Cr, up 17% YoY; strong performance in both Emerging and US/Regulated markets.

• H1 FY25 PAT surpassed ₹250 Cr for the first time, with Q2 FY25 PAT at ₹131 Cr, up 13% YoY.

• Expansion into oncology, peptides, insulin, biosimilars, specialty chemicals, medical devices, and software development, with a 3–5 year horizon for many initiatives.

• Focus on Latin America, U.S., and renewed entry into China, leveraging partnerships and backward integration.

• Maintained high compliance, supply chain efficiency, and a debt-free, cash-positive balance sheet.

Financial highlights

• Q2 FY25 consolidated revenue from operations: ₹483.1 Cr (up 17.8% YoY); H1 FY25: ₹942.1 Cr (up 17.0% YoY).

• Q2 FY25 PAT: ₹130.8 Cr (up 12.6% YoY); H1 FY25 PAT: ₹255.7 Cr (up 16.0% YoY).

• Gross margin for Q2 FY25: 60.9%; EBITDA margin: 36.8%; PAT margin: 26.0%.

• Free cash reserves stood at ₹1,039 Cr as of September 30, 2024; free cash flow for H1 FY25: ₹109 Cr.

• CapEx of ₹77 Cr in H1 FY25, funded entirely from internal accruals.

Outlook and guidance

• Confident in scaling up growth, with focus on larger LatAm markets (Mexico, Chile, Brazil) and U.S. B2C expansion.

• US business expected to remain B2B-dominant in near term, with gradual B2C ramp-up; $100 million US revenue target by FY27/FY28 remains on track.

• Plans to enter more regulated markets (Canada, Australia, MENA, Russia/CIS, Mexico, Brazil) in the near to medium term.

• New initiatives in oncology, biosimilars, and specialty products expected to crystallize over 3–5 years.

• Ongoing digitalization of manufacturing and quality systems to enhance compliance.